Aprepitant: A substance P antagonist for chemotherapy induced nausea and vomiting

Indian Journal of Cancer

Volumn 44, Issue 1, 2007, Pages 25-30

  Girish, C ^a   Manikandan, S ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Antiemetics; Aprepitant; Chemotherapy induced nausea and vomiting; Neurokinin

Indexed keywords

EID: 34047189666     PISSN: 0019509X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-509X.31164     Document Type: Review

References (32)

1. Kris MG. Why do we need another antiemetic? Just ask. J Clin Oncol 2003;21:4077-80.
2. The national comprehensive cancer network. Clinical practice guidelines. Antiemesis, version 1. 2005. Available from: http://www.nccn.org [Last accessed on 2005 Jun 1].
3. Rittenberg CN. A new class of antiemetic agents on the horizon. Clin J Oncol Nurs 2002;6:103-4.
4. Huskey SE, Dean BJ, Bakhtiar R, Sanohez RI, Tattersall FD, Rycroft W, et al. Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets. Drug Metab Dispos 2003;31785-91.
5. 3 antagonists and the additional value of NK1 antagonists: A new class of antiemetics. Br J Cancer 2003;88:1823-7.
6. Saito R, Takano Y, Kamiya HO. Roles of substance P and NK(1) receptor in brain stem in the development of emesis. J Pharmacol Sci 2003;91:87-94.
7. Massaro AM, Lenz KL. Aprepitant: A novel antiemetic for chemotherapy-induced nausea and vomiting. Ann Pharmacother 2005;39:77-85.
8. Navari RM. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting - Two new agents. J Support Oncol 2003;1:89-103.
9. th ed. McGraw-Hill: New York; 2007. p. 277-92.
10. Olver IN. Aprepitant in antiemetic combinations to prevent chemotherapy induced nausea and vomiting. Int J Clin Pract 2004;58:201-6.
11. Hargreaves R. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry 2002;63:18-24.
12. Krowicki ZK, Hornby PJ. Substance P in the dorsal motor nucleus of the vagus evokes gastric motor inhibition via neurokinin 1 receptor in rats. J Pharmacol Exp Ther 2000;293:214-21.
13. Sanger GJ. Neurokinin NK1 and NK3 receptors as targets for drugs for to treat gastrointestinal motility disorders and pain. Br J Pharmacol 2004;141:1303-12.
14. Majumdar AK, Howard L, Goldberg MR, Hickey L, Constanzer M, Rothenberg PL, et al. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol 2006;46:291-300.
15. Product information. Emend (Aprepitant). Merck: Whitehouse station, NJ; May 2003.
16. Aapro MS, Macciocchi A, Gridelli C. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients. J Support Oncol 2005;3:369-74.
17. Bergman AJ, Marbury T, Fosbinder T, Swan S, Hickey L, Bradstreet TE, et al. Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant. Clin Pharmacokinet 2005:44:637-47.
18. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-9.
19. McCrea JB, Majumdar AK, Goldberg MR, Iwamoto M, Gargano C, Panebianco DL, et al. Effect of the neurokinin 1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003;74:17-24.
20. Majumdar AK, McCrea JB, Panebianco DL, Hesney M, Dru J, Constanzer M, et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 2003;74:150-6.
21. Miners JO, Birkett DJ. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br J Clin pharmacol 1998;45:525-38.
22. Viale PH. Update on the management of chemotherapy-induced nausea and vomiting. J Infus Nurs 2006;29:283-92.
23. Watson JW, Gonsalves SF, Fossa AA, McLean S, Seeger T, Obach S, et al. The anti-emetic effects of CP-99, 994 in the ferret and the dog: Role of the NK1 receptor. Br J Pharmacol 1995;115:84-94.
24. Grelot L, Dapzol J, Esteve E, Frugiere A, Bianchi AL, Sheldrick RL, et al. Potent inhibition of both the acute and delayed emetic responses to cisplatin in piglets treated with GR205171, a novel highly selective tachykinin NK1 receptor antagonist. Br J Pharmacol 1998;124:1643-50.
25. Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med 1999;340:190-5.
26. Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001;19:1759-67.
27. Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 2002;94:3032-41.
28. Poll-Blgelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-8.
29. de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003;21:4105-11.
30. Herrstedt J, Muss HB, Warr DG, Hesketh PJ, Eisenberg PD, Raftopoulos H, et al. Aprepitant Moderately Emetogenic Chemotherapy Study Group: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005;104:1548-55.
31. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-30.
32. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-9.